Triple-Drug attack shows promise for tough colorectal cancer
NCT ID NCT04017650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy (nivolumab) in people with a specific type of advanced colorectal cancer (BRAF V600E mutation) that is stable (MSS) and has spread or can't be removed by surgery. The goal is to see if this triple therapy can shrink tumors better than standard treatment. About 38 adults with this hard-to-treat cancer are participating.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF NP_004324.2:P.V600E are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new blood test spot colorectal cancer return earlier?
- Experimental drug combo targets Hard-to-Treat GI cancers
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a pill help the liver regrow and make more cancer surgeries possible?
- Experimental combo targets Hard-to-Treat GI cancers
- Can a smaller dose of this cancer drug still work? new trial aims to find out